Development of a web application and a mobile app to improve breast cancer patient follow-up.
Together with AIM-Apps in Medicine GmbH, AOK Bayern, DAK Gesundheit and Siemens Betriebskrankenkasse (SBK), under the direction of the Klinikum rechts der Isar of the Technical University of Munich (MRI), BITS GmbH participated in the PRISMA study as a consortium partner for the technical infrastructure and developed the PRISMA portal and the “Meine Busenfreundin” app for this purpose. Thirty breast centers throughout Bavaria are participating in the associated study. PRISMA is funded with 3.46 million from the innovation fund of the Federal Joint Committee (GBA).
BITS’ tasks include all digital aspects, including technical IT project management, IT conception, IT architecture and development of the web portal for managing the study and the implementation of the digital questionnaires within the “Meine Busenfreundin” app.
BITS as consortium partner
“Together with BITS GmbH as technical partner for the development of the PRISMA portal and mobile app, we have successfully started the PRISMA study. We want to use this new form of care to improve the quality of life and treatment adherence of breast cancer patients.”
BITS as consortium partner
“Together with BITS GmbH as technical partner for the development of the PRISMA portal and mobile app, we have successfully started the PRISMA study. We want to use this new form of care to improve the quality of life and treatment adherence of breast cancer patients.”
Challenge
Realization
As one of the consortium partners, BITS is responsible for the technical implementation of the digital infrastructure in the project funded by the innovation fund of the Federal Joint Committee (GBA). In addition to IT project management, our tasks include IT conception, IT architecture and development of the web portal to manage the study and the implementation of the digital questionnaires within the app “Meine Busenfreundin”. The app is connected via an interface to the newly developed, web-based platform PRISMA, to which only the treating breast center has access. If the patient repeatedly makes conspicuous statements, PRISMA informs the breast center. There, a specialist can then contact the patient directly and provide advice. Initially, this will be investigated in 400 female subjects as part of a study. Half will use the app and the other half will receive conventional follow-up. By comparing these two groups in terms of treatment adherence and quality of life, the benefits of digital care will be examined.